Garetosmab ( DrugBank: Garetosmab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 272 | 進行性骨化性線維異形成症 | 2 |
272. 進行性骨化性線維異形成症
臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05394116 (ClinicalTrials.gov) | November 21, 2022 | 4/5/2022 | The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva | Fibrodysplasia Ossificans Progressiva | Drug: Garetosmab;Drug: Placebo | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 66 | Phase 3 | Japan;Poland;Spain;United Kingdom |
| 2 | NCT04577820 (ClinicalTrials.gov) | October 13, 2021 | 30/9/2020 | Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) | Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva | Fibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO) | Drug: garetosmab | Regeneron Pharmaceuticals | NULL | Withdrawn | 18 Years | 60 Years | All | 0 | Phase 3 | NULL |